TY - JOUR
T1 - Molecular profiling of breast cancer
AU - Cyr, Amy E.
AU - Margenthaler, Julie A.
PY - 2014/7
Y1 - 2014/7
N2 - Breast cancer is now considered a heterogeneous and phenotypically diverse disease. Molecular profiling is used in clinical practice in 2 broad categories: (1) characterization of breast cancers beyond the standard histopathologic features such as tumor grade, histologic subtype, and biomarker profile for prognostic information; and (2) prediction of response to therapy and clinical outcome. This article addresses the importance and application of molecular subtype analysis, and provides an in-depth analysis of the clinical application of the molecular prognostic indices for ductal carcinoma in situ, node-negative invasive breast cancer, and node-positive invasive breast cancer.
AB - Breast cancer is now considered a heterogeneous and phenotypically diverse disease. Molecular profiling is used in clinical practice in 2 broad categories: (1) characterization of breast cancers beyond the standard histopathologic features such as tumor grade, histologic subtype, and biomarker profile for prognostic information; and (2) prediction of response to therapy and clinical outcome. This article addresses the importance and application of molecular subtype analysis, and provides an in-depth analysis of the clinical application of the molecular prognostic indices for ductal carcinoma in situ, node-negative invasive breast cancer, and node-positive invasive breast cancer.
KW - Breast cancer
KW - Genome
KW - Molecular diagnostics
KW - Molecular profiling
KW - Prognostication
UR - http://www.scopus.com/inward/record.url?scp=84901676155&partnerID=8YFLogxK
U2 - 10.1016/j.soc.2014.03.004
DO - 10.1016/j.soc.2014.03.004
M3 - Review article
C2 - 24882344
AN - SCOPUS:84901676155
SN - 1055-3207
VL - 23
SP - 451
EP - 462
JO - Surgical Oncology Clinics of North America
JF - Surgical Oncology Clinics of North America
IS - 3
ER -